The asparaginyl hydroxylase factor-inhibiting HIF is essential for tumor growth through suppression of the p53-p21 axis

Oncogene

Volumn 31, Issue 24, 2012, Pages 2989-3001

  Pelletier, J ^a   Dayan, F ^a,b   Durivault, J ^a   Ilc, K ^a   Pecou E ^b   Pouyssegur J ^a   Mazure, N M ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b UNIVERSITÉ DE NICE SOPHIA ANTIPOLIS   (France)

Author keywords

FIH; HIF 1; hypoxia; p53; tumor growth

Indexed keywords

ASPARAGINYL HYDROXYLASE FACTOR; CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR; PROTEIN INHIBITOR; PROTEIN P21; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CELL MUTANT; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR CELL; TUMOR GROWTH;

ADENOCARCINOMA; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MELANOMA; MIXED FUNCTION OXYGENASES; NEOPLASMS; OXYGEN; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862325401     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.471     Document Type: Article

References (40)

1. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. (2003). HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22: 4082-4090. (Pubitemid 37021737)
2. Brady CA, Attardi LD. (2010). p53 at a glance. J Cell Sci 123: 2527-2532.
3. Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM et al. (2009). Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 69: 358-368.
4. Cockman ME, Lancaster DE, Stolze IP, Hewitson KS, McDonough MA, Coleman ML et al. (2006). Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc Natl Acad Sci USA 103: 14767-14772. (Pubitemid 44527803)
5. Cockman ME, Webb JD, Ratcliffe PJ. (2009). FIH-dependent asparaginyl hydroxylation of ankyrin repeat domain-containing proteins. Ann NY Acad Sci 1177: 9-18.
6. Dayan F, Mazure NM, Brahimi-Horn MC, Pouyssegur J. (2008). A dialogue between the hypoxia-inducible factor and the tumor microenvironment. Cancer Microenviron 1: 53-68.
7. Dayan F, Monticelli M, Pouyssegur J, Pecou E. (2009). Gene regulation in response to graded hypoxia: the non-redundant roles of the oxygen sensors PHD and FIH in the HIF pathway. J Theor Biol 259: 304-316.
8. Dayan F, Roux D, Brahimi-Horn MC, Pouyssegur J, Mazure NM. (2006). The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res 66: 3688-3698.
9. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. (1997). A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 94: 4273-4278.
10. Fels DR, Koumenis C. (2005). HIF-1alpha and p53: the ODD couple? Trends Biochem Sci 30: 426-429.
11. Flamme I, Frohlich T, von Reutern M, Kappel A, Damert A, Risau W. (1997). HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech Dev 63: 51-60. (Pubitemid 27214502)
12. Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M et al. (1997). Characterization of a subset of the basi-chelix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J Biol Chem 272: 8581-8593. (Pubitemid 27147824)
13. Hu CJ, Sataur A, Wang L, Chen H, Simon MC. (2007). The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Mol Biol Cell 18: 4528-4542. (Pubitemid 350060179)
14. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ et al. (2001). Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472. (Pubitemid 32335942)
15. Kaluz S, Kaluzova M, Stanbridge EJ. (2008). Comment on the role of FIH in the inhibitory effect of bortezomib on hypoxia-inducible factor-1. Blood 111: 5258-5259.
16. Koivunen P, Hirsila M, Gunzler V, Kivirikko KI, Myllyharju J. (2003). Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 279: 9899-9904. (Pubitemid 38372589)
17. Kroeze SG, Vermaat JS, van Brussel A, van Melick HH, Voest EE, Jonges TG et al. (2010). Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients. Eur J Cancer 46: 3375-3382.
18. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. (2002a). FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16: 1466-1471. (Pubitemid 34686328)
19. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. (2002b). Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295: 858-861. (Pubitemid 34118367)
20. Linke S, Stojkoski C, Kewley RJ, Booker GW, Whitelaw ML, Peet DJ. (2004). Substrate requirements of the oxygen-sensing asparaginyl hydroxylase factor inhibiting HIF. J Biol Chem 279: 14391-14397. (Pubitemid 38468981)
21. Liu CJ, Tsai MM, Hung PS, Kao SY, Liu TY, Wu KJ, Chiou SH, Lin SC, Chang KW. (2010). miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res 70: 1635-1644.
22. Lisy K, Peet DJ. (2008). Turn me on: regulating HIF transcriptional activity. Cell Death Differ 15: 642-649. (Pubitemid 351405067)
23. Mahon PC, Hirota K, Semenza GL. (2001). FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675-2686. (Pubitemid 32988878)
24. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ et al. (2005). Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105: 659-669. (Pubitemid 40070750)
25. Morris MR, Maina E, Morgan NV, Gentle D, Astuti D, Moch H et al. (2004). Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J Clin Pathol 57: 706-711. (Pubitemid 38901484)
26. Newbold RF. (2002). The significance of telomerase activation and cellular immortalization in human cancer. Mutagenesis 17: 539-550.
27. O'Rourke JF, Tian YM, Ratcliffe PJ, Pugh CW. (1999). Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1alpha. J Biol Chem 274: 2060-2071.
28. Pouyssegur J, Dayan F, Mazure NM. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443. (Pubitemid 44050138)
29. Sakamoto T, Seiki M. (2009). Mint3 enhances the activity of hypoxia-inducible factor-1 (HIF-1) in macrophages by suppressing the activity of factor inhibiting HIF-1. J Biol Chem 284: 30350-30359.
30. Schodel J, Bohr D, Klanke B, Schley G, Schlotzer-Schrehardt U, Warnecke C et al. (2010). Factor inhibiting HIF limits the expression of hypoxia-inducible genes in podocytes and distal tubular cells. Kidney Int 78: 857-867.
31. Semenza GL. (2010). HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51-56.
32. Shin DH, Chun YS, Lee DS, Huang LE, Park JW. (2008). Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111: 3131-3136.
33. Tian H, McKnight SL, Russell DW. (1997). Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11: 72-82. (Pubitemid 27043825)
34. Tian YM, Yeoh KK, Eriksson T, Kessler BM, Kramer HB, Edelmann MJ et al. (2011). Differential sensitivity of hypoxia factor hydroxylation sites to hypoxia and hydroxylase inhibitors. J Biol Chem 286: 13041-13051.
35. van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, van Leenen D et al. (2003). Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 4: 609-615. (Pubitemid 36939953)
36. Vousden KH, Prives C. (2009). Blinded by the light: the growing complexity of p53. Cell 137: 413-431.
37. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL et al. (1998). Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 92: 2260-2268. (Pubitemid 28452966)
38. Wiznerowicz M, Trono D. (2003). Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 77: 8957-8961. (Pubitemid 36936105)
39. Yan J, Jiang J, Lim CA, Wu Q, Ng HH, Chin KC. (2007). BLIMP1 regulates cell growth through repression of p53 transcription. Proc Natl Acad Sci USA 104: 1841-1846. (Pubitemid 46239866)
40. Zhang N, Fu Z, Linke S, Chicher J, Gorman JJ, Visk D et al. (2010). The asparaginyl hydroxylase factor inhibiting HIF-1alpha is an essential regulator of metabolism. Cell Metab 11: 364-378.